Drug intelligence / Profile preview

GENImmune

Development stage: Unknown
Lead developer: IMMUNEO Therapeutics
Modality: Peptides, Vaccines & Immunotherapeutics

Overview

GENImmune is a peptide-based immunization developed by IMMUNEO Therapeutics for the prevention or treatment of COVID-19 (SARS-CoV-2). The vaccine is designed to target specific SARS-CoV-2 epitopes to elicit a targeted antiviral immune response. According to the developer's pipeline, the development program for GENImmune is listed as completed, although specific clinical trial phases are not explicitly detailed in the provided source material.

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on GENImmune.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GENImmune.

Explore the full profile